Astellas Pharma Clinical Trials

Clinical trials sponsored by Astellas Pharma — phases, conditions and reported results. Data from ClinicalTrials.gov.

• A Trial of Androgen Deprivation, Docetaxel, and Enzalutamide for Metastatic Prostate Cancer
  Phase 2 · Prostate Cancer · Active, not recruiting · Sep 22, 2023
• An Efficacy and Safety Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT i
  Phase 3 · Metastatic Hormone Sensitive Prostate Cancer · Active, not recruiting · Nov 18, 2023
• Gilteritinib vs Midostaurin in FLT3 Mutated Acute Myeloid Leukemia
  Phase 2 · Acute Myeloid Leukemia · Completed · Feb 28, 2025
• A Study of ASP2215 Versus Salvage Chemotherapy In Patients With Relapsed or Refractory Acute Myeloid Leukemia
  Phase 3 · AML With FLT3 Mutation · Active, not recruiting · Jan 14, 2025
• A Study of Zolbetuximab (IMAB362) Plus CAPOX Compared With Placebo Plus CAPOX as First-line Treatment of Subje
  Phase 3 · Locally Advanced Unresectable Gastroesophageal Junction Adenocarcinoma or Cancer · Active, not recruiting · Jan 27, 2025
• A Study of ASP2215 (Gilteritinib) by Itself, ASP2215 Combined With Azacitidine or Azacitidine by Itself to Tre
  Phase 3 · Acute Myeloid Leukemia · Completed · Sep 12, 2025
• Safety and Efficacy Study of Enzalutamide Plus Leuprolide in Patients With Nonmetastatic Prostate Cancer (EMBA
  Phase 3 · Hormone Sensitive Prostate Cancer · Active, not recruiting · Mar 25, 2024
• Perioperative Pembrolizumab (MK-3475) Plus Cystectomy or Perioperative Pembrolizumab Plus Enfortumab Vedotin P
  Phase 3 · Urinary Bladder Cancer, Muscle-invasive · Active, not recruiting · Jun 30, 2026
• A Safety and Efficacy Study of Enzalutamide in Indian Patients With Progressive Metastatic Castration-Resistan
  Phase 4 · Metastatic Castration Resistant Prostate Cancer · Completed · Jan 23, 2025
• A Study to Evaluate Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Malignant Solid Tumors
  Phase 2 · Locally Advanced or Metastatic Malignant Solid Tumors · Active, not recruiting · Apr 13, 2026
• Enfortumab Vedotin and Pembrolizumab vs. Chemotherapy Alone in Untreated Locally Advanced or Metastatic Urothe
  Phase 3 · Urothelial Cancer · Active, not recruiting · Sep 27, 2024
• Avacincaptad Pegol Open-Label Extension for Patients With Geographic Atrophy
  Phase 3 · Geographic Atrophy · Completed · Apr 14, 2026
• A Study to Compare Zolbetuximab (IMAB362) and Chemotherapy With Placebo and Chemotherapy in Adults With Gastri
  Phase 3 · Locally Advanced Unresectable Gastroesophageal Junction Adenocarcinoma or Cancer · Active, not recruiting · Feb 26, 2025
• Talazoparib + Enzalutamide vs. Enzalutamide Monotherapy in mCRPC
  Phase 3 · mCRPC · Active, not recruiting · Jan 17, 2024
• Zimura Compared to Sham in Patients With Autosomal Recessive Stargardt Disease (STGD1)
  Phase 2 · Stargardt's Macular Dystrophy · Completed · Mar 12, 2026

Trials by company

PfizerMerck (MSD)RocheNovartisAstraZenecaJohnson & Johnson (Janssen)Bristol Myers SquibbSanofiGSKEli LillyAbbVieAmgenBayerBoehringer IngelheimNovo NordiskTakedaGilead SciencesModernaBioNTechRegeneronVertexBiogenDaiichi SankyoAstellas PharmaEisaiOtsukaServierIncyteCelltrionSamsung BioepisHanmi PharmaceuticalYuhan

All trials